• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Enveric Biosciences Appoints Dr. Bob Dagher as Chief Medical Officer

    12/6/21 7:30:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENVB alert in real time by email

    NAPLES, Fla., Dec. 6, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced the appointment of Bob Dagher, MD, as Chief Medical Officer, effective immediately.

    Dr. Dagher brings over 20 years of experience working in clinical development in the pharmaceutical industry for both small and large pharmaceutical companies and as a board-certified physician from the American Board of neurology and psychiatry. He has an extensive therapeutic background concentrated in the neuroscience space which includes a focus on psychotic, affective and anxiety disorders, as well as neuroimmunology, neurodegeneration and movement disorders. Furthermore, Dr. Dagher has supported and driven successful drug development programs from preclinical stages through Phase 4 clinical trials.

    "Dr. Dagher joins our team at a crucial time where we are continuing to build momentum and drive development of our key psychedelic molecules for the mind and cannabinoids for the body," said Dr. Joseph Tucker, Chief Executive Officer, Enveric Biosciences. "Dr. Dagher brings extensive experience working in the pharmaceutical industry with a focus and passion for drug development for neurological and mental health indications. His experience is expected to be very valuable as he will lead Enveric alongside our clinical team in continuing to advance our pipeline. Dr. Dagher's addition to Enveric is key addition as we continue our focus on building a world-class management team."

    "As a trailblazing Company working to discover and develop the next-generation treatments through the use of both psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, Enveric has major potential to make a real difference for mental health and cancer patients in need," said Dr. Dagher. "As Chief Medical Officer, I look forward to working with the leadership and clinical teams to harness the power of these groundbreaking technologies to truly help bring solutions to various indications ranging from cancer-related distress to a whole host of other mental health disorders."

    Prior to joining Enveric, Dr. Dagher served as the Chief Medical Officer at WCG MedAvante-ProPhase where he led the clinical science organization to help forge and develop compelling scientific solutions to match industry challenges. Before joining WCG, Dr. Dagher served as the Chief Medical Officer at Cadent Therapeutics, where he led and advanced the company's pipeline of small molecules, coupled with the implementation of precision biomarkers, for the development of innovative programs in rare diseases and common indications targeting movement and cognitive disorders.  Following his early experience treating patients in academic and private practice settings, Dr. Dagher started his career in the pharmaceutical industry at GlaxoSmithKline, followed by Sanofi/Genzyme working on neurology, psychiatry, and urology indications.

    Robert Wilkins, MD, stepped down from his role of Chief Medical Officer on November 29th, 2021. David Johnson, Executive Chairman, stated, "I want to thank Robert for his commitment to Enveric over the past two years. His contributions to our team have been significant and meaningful. His leadership has helped guide our transformation into the biotechnology company we are today. We relied on Robert's expertise having worked with several biomedical startups in the past and have valued his deep knowledge in the pharmaceutical space. His guidance and insights have helped shape Enveric's leadership team. We are grateful for the significant contributions he has made to Enveric and wish him the best of luck on his future endeavors."

    About Enveric Biosciences

    Enveric Biosciences (NASDAQ:ENVB) is an innovative biotechnology company developing next-generation mental health and oncology treatments and clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric's robust pipeline supports drug discovery efforts and clinical development programs to enable potential commercialization of effective treatments for millions of patients in need around the world. For more information, please visit www.enveric.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans", " expects" or "does not expect", "proposed", "is expected", "budgets", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric's ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric's ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. 

    Investor Contacts

    Valter Pinto / Allison Soss

    KCSA Strategic Communications

    212.896.1254 / 212.896.1267

    [email protected] / [email protected] 

    Media Contacts

    Raquel Cona

    KCSA Strategic Communications

    212.896.1204

    [email protected] 

     

    Cision View original content:https://www.prnewswire.com/news-releases/enveric-biosciences-appoints-dr-bob-dagher-as-chief-medical-officer-301437503.html

    SOURCE Enveric Biosciences

    Get the next $ENVB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ENVB

    DatePrice TargetRatingAnalyst
    3/8/2022$7.00 → $0.20Buy → Hold
    Aegis Capital
    7/8/2021$7.00Buy
    Aegis Capital
    6/28/2021$6.00Buy
    Maxim Group
    More analyst ratings

    $ENVB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

      EB-003 revealed to also act as an agonist of the serotonin receptor 5-HT1B, a validated target of drugs approved to treat major depressive disorder and a variety of neurological conditions including Parkinson's disease, migraines, and cluster headaches Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today unveiled additional data indicating that its lead development candidate, EB-003, acts as an agonist of the serotonin receptor 5-HT1B, in addition to its other previously disclosed receptor engagement activi

      6/24/25 9:03:00 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enveric Biosciences Announces Participation in 2025 BIO International Convention

      Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts. During the conference, CEO and Director of Enveric, Joseph Tucker, Ph.D., will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and development strategy, recent corporate achievements, and anticipated milestones. About Enveric Biosciences Enveric Bioscience

      6/16/25 10:46:00 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

      Patent-protected aminated tryptamine derivatives strengthen Enveric's leadership in next-generation mental health treatments Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering compositions of matter and methods of use for a novel class of aminated tryptamine derivatives. The patented compounds were designed through Enveric's proprietary discovery platform and represent a first-in-class approach to non-h

      6/10/25 9:03:00 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF INNOVATION OFFICER Facchini Peter J. was granted 24,717 shares, increasing direct ownership by 296% to 33,058 units (SEC Form 4)

      4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

      5/12/25 5:00:16 PM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF FINANCIAL OFFICER Coveney Kevin Michael was granted 74,150 shares, increasing direct ownership by 596% to 86,584 units (SEC Form 4)

      4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

      5/12/25 5:00:20 PM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Tucker Joseph Edward was granted 98,866 shares, increasing direct ownership by 453% to 120,711 units (SEC Form 4)

      4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

      5/12/25 5:00:06 PM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Enveric Biosciences downgraded by Aegis Capital with a new price target

      Aegis Capital downgraded Enveric Biosciences from Buy to Hold and set a new price target of $0.20 from $7.00 previously

      3/8/22 9:32:53 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital initiated coverage on Enveric Biosciences with a new price target

      Aegis Capital initiated coverage of Enveric Biosciences with a rating of Buy and set a new price target of $7.00

      7/8/21 9:31:19 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Enveric Biosciences with a new price target

      Maxim Group initiated coverage of Enveric Biosciences with a rating of Buy and set a new price target of $6.00

      6/28/21 8:59:11 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENVB
    SEC Filings

    See more
    • Enveric Biosciences Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Enveric Biosciences, Inc. (0000890821) (Filer)

      6/3/25 4:30:18 PM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Enveric Biosciences Inc.

      10-Q - Enveric Biosciences, Inc. (0000890821) (Filer)

      5/14/25 4:59:36 PM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enveric Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Enveric Biosciences, Inc. (0000890821) (Filer)

      5/14/25 4:15:30 PM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENVB
    Leadership Updates

    Live Leadership Updates

    See more
    • Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

      Second biotechnology company to potentially out-license novel compounds from Enveric's portfolio of assets with possible significant milestone payments and royalties Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is pleased to announce that it has signed two non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmaceutical applications for treatment of joint diseases. The term sheets c

      3/19/24 7:00:00 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

      30+ year pharmaceutical industry veteran joins Enveric's executive team to lead company's financial and capital markets activities. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today the appointment of Kevin Coveney, CPA, to the position of Chief Financial Officer, effective March 13, 2023. Mr. Coveney brings 30+ years of accounting, finance, and operations experience to Enveric, having previously served as Chief Financial Officer for multiple biotechnology companies. As CFO, Mr. Coveney will be responsibl

      2/28/23 7:30:00 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

      Accomplished pharmaceutical industry leader brings to Enveric extensive experience in clinical operations, asset strategy and product development Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today the appointment of Lynn Gallant to the position of Vice President, Clinical Operations. Ms. Gallant brings more than 25 years of clinical operations and trial management experience to Enveric and will work alongside Bob Dagher, M.D., Chief Medical Officer, to oversee the ongoing development of the company's EVM201

      2/23/23 7:33:00 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENVB
    Financials

    Live finance-specific insights

    See more
    • Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

      Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Started IND-enabling preclinical activities for EB-002 and completed important repeat-dose toxicology studies, genotoxicity studies, and key cardiac, respiratory, and CNS safety pharmacology studies. Corporate and Business Development Highlights: Signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds from the Company's extensive portfolio of assets. Signe

      3/26/24 7:00:00 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights

      Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 Continued to advance pipeline of small molecule therapeutics for the treatment of mental health disorders, including EB-373 for the treatment of anxiety disorder and EVM301 Series Announced termination of proposed spin-off of cannabinoid clinical development pipeline to publicly traded company; Enveric now engaging with strategic advisors to identify and pursue alternative value-creating opportunities for cannabinoid assets Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of

      5/15/23 9:25:00 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders

      The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the confidential submission of a Form S-1 draft registration statement with the U.S. Securities and Exchange Commission (‘SEC') for the spin-off its cannabinoid clinical development pipeline to a wholly-owned subsidiary, Akos Biosciences, Inc. (‘Akos'),

      11/28/22 7:30:00 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Pasqualone Frank bought $2,140 worth of shares (1,000 units at $2.14)

      4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

      9/19/23 5:34:00 PM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

      SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

      11/14/24 4:03:47 PM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

      SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

      11/13/24 11:18:03 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

      SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

      11/12/24 1:43:47 PM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care